Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]
Discontinued
Reference number: GID-TA10591
The Department for Health and Social Care has asked NICE to carry out an appraisal of pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer ID2711.
For information, the company have announced that pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer ID2711 did not meet its primary endpoint and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time.
Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.